{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-003772","form_type":"8-K","ticker":"KOD","cik":"0001468748","company_name":"Kodiak Sciences Inc.","filed_at":"2021-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.666704+00:00","generated_at":"2026-06-28T10:36:49.626362+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Kodiak Q3 net loss $67.5M ($1.30/shr); cash $799M; pipeline on track for 2022 readouts","bullets":["Net loss widened to $67.5M ($1.30/shr) from $36.1M ($0.80/shr) in Q3 2020.","R&D expenses rose to $56.0M (vs $29.3M) on KSI-301 trial and manufacturing costs.","Cash and equivalents $799.2M; no revenue reported.","DAZZLE (wet AMD) topline data expected Q1 2022; BEACON (RVO) mid-2022.","GLEAM/GLIMMER (DME) enrollment target Q1 2022; DAYLIGHT (wet AMD) enrollment 1H 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-003772","json":"https://secwatch.observer/filing/0000950170-21-003772.json","markdown":"https://secwatch.observer/filing/0000950170-21-003772.md","text":"https://secwatch.observer/filing/0000950170-21-003772.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468748/000095017021003772/0000950170-21-003772-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468748/000095017021003772/kod-20211109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T10:36:49.626362+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}